FDA And CMS Missions Converge In The Postmarket Arena – FDA’s Gottlieb
This article was originally published in The Gray Sheet
Executive Summary
Development of postmarket studies represents the best opportunity for CMS and FDA to collaborate and streamline the regulatory and reimbursement process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
You may also be interested in...
HRS Moves From Successful Policy Meeting Toward Physician Guidelines
The Heart Rhythm Society hopes to complete physician guidelines on managing device safety alerts by late spring 2006, according to the chair of the committee developing the guidelines, Mark Carlson, MD, Case Western Reserve University
Acting Chief von Eschenbach Brings Zeal For Imaging To FDA
Andrew von Eschenbach's role in supporting the development of imaging and other diagnostic technology as director of the National Cancer Institute could inform his approach to medical device regulatory issues as he takes on the added role of acting FDA commissioner
CMS Will Review National Coverage Request For ICD Risk Stratification Tool
Medicare coverage of Microvolt T-Wave Alternans (MTWA)testing for ICD-eligible patients could increase the number of defibrillators implanted in patients at high risk for sudden cardiac death, according to Cambridge Heart